Last reviewed · How we verify

NCT06564727

Uniportal VATS Resection for Pulmonary Aspergilloma : Evaluation of Prognostic Factors in a Single Center Experience

Completed NA Last updated 21 August 2024
What this trial tests

NA trial testing Uniportal VATS approach in Pulmonary Aspergillosis in 51 participants. Completed in 30 January 2020.

Timeline
1 January 2017
Primary endpoint
1 January 2020
30 January 2020

Quick facts

Lead sponsorHassan II University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment51
Start date1 January 2017
Primary completion1 January 2020
Estimated completion30 January 2020
Sites1 location across Morocco

Drugs / interventions tested

Conditions studied

Sponsor

Hassan II University

Who can join

Eligibility, any sex, with Pulmonary Aspergillosis or Surgery-Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study was to report our experience with U-VATS resection and to evaluate our surgical outcomes with an analysis of postoperative complications. The investigators also estimate the prognostic factors that influence the morbidity and the conversion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pulmonary Aspergillosis

Currently open trials in the same condition.

Other Hassan II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06564727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing